Developing an innovative biologic for two major regulatory markets can sometimes feel like solving the same problem twice. FDA and EMA may ask similar questions, but that does not mean they will always give the same answers. That is where Parallel Scientific Advice (PSA) can make the development conversation much more coordinated. Instead of navigating … Read more
For medical device companies, FDA review time is more than a number on a performance chart, it can determine how quickly an innovation reaches patients. MDUFA V promised to make the regulatory process more efficient, predictable, and transparent. Now, an independent assessment by Booz Allen Hamilton provides a detailed look at what actually changed. The … Read more
Navigating the complex landscape of medical device regulation has always required immense patience, meticulous documentation, and strategic foresight. For years, medical device innovators have wrestled with customized submission formats that slow down the journey from breakthrough concept to patient care. Fortunately, the FDA is actively reshaping this journey with a streamlined, digitized approach to market … Read more
For decades, bringing a new drug to market meant one inevitable, heartbreaking reality: rows of laboratory animals sacrificed in the name of safety. Now, a sweeping regulatory shift by the FDA promises to usher in a modern era where computer models and organ chips take center stage. But before animal rights advocates pop the champagne, … Read more
Bringing a novel medical device from the whiteboard to the operating room is an exhilarating journey, but it frequently hits an abrupt wall at regulatory review. Developers often assume that running a standard battery of laboratory tests will automatically satisfy agency reviewers. In reality, the FDA does not evaluate safety in a vacuum; they evaluate … Read more
In the world of medical research, prespecified primary outcomes are supposed to be the immovable target that ensures scientific honesty. Yet, historical monitoring of thousands of clinical trials has long been bogged down by tedious manual curation. Enter the power of artificial intelligence, bringing unprecedented scale to the oversight of clinical evidence. A groundbreaking new … Read more
Every time a new technological marvel enters the medical arena, there are anxieties about obsolescence. Today, as artificial intelligence begins outperforming humans on complex diagnostic tasks and supporting autonomous medical care agents, there is talk of role of medical professionals on clinical care. A recent perspective in the New England Journal of Medicine argues that, … Read more
Receiving an official Warning Letter from the FDA is a defining moment that can permanently shatter a company’s reputation and bottom line. For Happy Farm Botanicals, Inc., an over-the-counter (OTC) drug manufacturer based in Hyattsville, Maryland, a September 1, 2026, warning letter proved to be the final straw. What began as routine compliance oversight ended … Read more
Navigating the transition from drug approval to market substitution requires a clear understanding of how regulatory bodies evaluate therapeutic equivalence. The FDA’s latest guidance on the topic gives drug sponsors a transparent view into how the agency assigns Orange Book codes. Understanding these principles is vital for biopharma executives, regulatory teams, and commercial strategists looking … Read more
Navigating the clinical trial landscape requires balancing groundbreaking innovation with extreme financial burden, particularly when manufacturing costs threaten to stall development. The FDA offers a formal pathway to recover direct costs for investigational drugs and devices without triggering allegations of premature commercialization, whereby the sponsor can get FDA’s approval to charge for its investigational drugs … Read more
